» Articles » PMID: 26825922

Long-Term Follow-Up Results From PET/CT Surveillance After Surgical Resection of Lung Adenocarcinoma Manifesting As Ground-Glass Opacity

Overview
Specialty General Medicine
Date 2016 Jan 31
PMID 26825922
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of our study was to retrospectively evaluate the value of F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for postoperative surveillance of lung adenocarcinoma manifesting as ground-glass opacity (GGO).From May 2003 to December 2007, 111 patients with surgically resected lung adenocarcinoma manifesting as GGO were included. Clinical findings of recurrence and survival, CT features, and maximum standardized uptake value (SUVmax) were reviewed and compared among 3 groups according to GGO proportion: Group I, GGO 100%; Group II, GGO ≥50%; Group III, GGO < 50%. Disease-free survival (DFS) was estimated using the Kaplan-Meier method. Diagnostic performances of CT and PET/CT for recurrence were compared during a long-term follow-up period of >5 years.Recurrence was identified in Group III (18 of 53, 34%) but not in Groups I (n = 25) or II (n = 33) over a mean follow-up period of 74 months. Group showed significant differences in GGO proportion, SUVmax, and DFS duration (P < 0.001). PET/CT led to 6 false-positive and 5 false-negative interpretations of recurrence. For surveillance CT, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 94.4%, 98.6%, 98.2%, 94.4%, and 98.9%, respectively; for PET/CT, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 72.2%, 92.3%, 88.5%, 68.4%, and 93.5%, respectively. CT showed significantly higher accuracy than PET/CT (P = 0.0188).FDG-PET/CT showed no clear advantage for postoperative surveillance of lung cancer with predominant GGO because of low incidence of recurrence and frequent false-positive and false-negative results.

Citing Articles

Value of window technique in diagnosis of the ground glass opacities in patients with non-small cell pulmonary cancer.

Yao G Oncol Lett. 2016; 12(5):3933-3935.

PMID: 27895751 PMC: 5104212. DOI: 10.3892/ol.2016.5133.


Long-term Follow-up Results from PET/CT Surveillance after Surgical Resection of Lung Adenocarcinoma Manifesting as Ground-glass Opacity: Notice of Retraction.

Medicine (Baltimore). 2016; 95(15):e6038.

PMID: 27243049 PMC: 4839869. DOI: 10.1097/01.md.0000482777.50860.38.

References
1.
Okada M, Nishio W, Sakamoto T, Uchino K, Hanioka K, Ohbayashi C . Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas. J Thorac Cardiovasc Surg. 2004; 127(3):857-61. DOI: 10.1016/j.jtcvs.2003.08.048. View

2.
Hellwig D, Groschel A, Graeter T, Hellwig A, Nestle U, Schafers H . Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2005; 33(1):13-21. DOI: 10.1007/s00259-005-1919-4. View

3.
Kim T, Park C, Goo J, Lee K . Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity?. AJR Am J Roentgenol. 2011; 198(1):83-8. DOI: 10.2214/AJR.11.6862. View

4.
Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S . Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 129(6):1226-31. DOI: 10.1016/j.jtcvs.2004.10.032. View

5.
Ko K, Hsu H, Huang T, Gao H, Cheng C, Hsu Y . Predictive value of 18F-FDG PET and CT morphologic features for recurrence in pathological stage IA non-small cell lung cancer. Medicine (Baltimore). 2015; 94(3):e434. PMC: 4602644. DOI: 10.1097/MD.0000000000000434. View